glycovax-002
Vaccineexperimental
Clinical trial activity
1 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 28, 2023 (NCT05799651)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
immunity, active - Sars-cov-2
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05799651 | Phase 1 | Apr 28, 2023 | Avance Clinical Pty Ltd., Glycovax Pharma, Government of Canada, JSS Medical Research Inc., Nucleus Network Ltd, SEPPIC, Paris |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Avance Clinical Pty Ltd. | For profit | 1 | 0 | 1 | 2023 |
| Glycovax Pharma | For profit | 1 | 1 | 1 | 2023 |
| Government of Canada | Government | 1 | 0 | 1 | 2023 |
| JSS Medical Research Inc. | For profit | 1 | 0 | 1 | 2023 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2023 |
| SEPPIC, Paris | For profit | 1 | 0 | 1 | 2023 |
6 organizations
Page 1 / 1